These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 30090093)

  • 1. Proposal of Classification Criteria for HTLV-1-Associated Myelopathy/Tropical Spastic Paraparesis Disease Activity.
    Sato T; Yagishita N; Tamaki K; Inoue E; Hasegawa D; Nagasaka M; Suzuki H; Araya N; Coler-Reilly A; Hasegawa Y; Tsuboi Y; Takata A; Yamano Y
    Front Microbiol; 2018; 9():1651. PubMed ID: 30090093
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chitotriosidase 1 in the cerebrospinal fluid as a putative biomarker for HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) progression.
    Gomes YCP; Freitas NL; Souza FS; Sandim V; Pereira DA; Nogueira FCS; Echevarria-Lima J; Leite ACCB; Lima MASD; Silva MTT; Araújo AQC; Vicente ACP; Espíndola OM
    Front Immunol; 2022; 13():949516. PubMed ID: 36052089
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CSF CXCL10, CXCL9, and neopterin as candidate prognostic biomarkers for HTLV-1-associated myelopathy/tropical spastic paraparesis.
    Sato T; Coler-Reilly A; Utsunomiya A; Araya N; Yagishita N; Ando H; Yamauchi J; Inoue E; Ueno T; Hasegawa Y; Nishioka K; Nakajima T; Jacobson S; Izumo S; Yamano Y
    PLoS Negl Trop Dis; 2013; 7(10):e2479. PubMed ID: 24130912
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Following the Clues: Usefulness of Biomarkers of Neuroinflammation and Neurodegeneration in the Investigation of HTLV-1-Associated Myelopathy Progression.
    Souza FDS; Freitas NL; Gomes YCP; Torres RC; Echevarria-Lima J; da Silva-Filho IL; Leite ACCB; de Lima MASD; da Silva MTT; Araújo AQC; Espíndola OM
    Front Immunol; 2021; 12():737941. PubMed ID: 34764955
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cerebrospinal Fluid CXCL10 as a Candidate Surrogate Marker for HTLV-1-Associated Myelopathy/Tropical Spastic Paraparesis.
    Tamaki K; Sato T; Tsugawa J; Fujioka S; Yagishita N; Araya N; Yamauchi J; Coler-Reilly ALG; Nagasaka M; Hasegawa Y; Yamano Y; Tsuboi Y
    Front Microbiol; 2019; 10():2110. PubMed ID: 31572323
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An update on human T-cell leukemia virus type I (HTLV-1)-associated myelopathy/tropical spastic paraparesis (HAM/TSP) focusing on clinical and laboratory biomarkers.
    Yamauchi J; Araya N; Yagishita N; Sato T; Yamano Y
    Pharmacol Ther; 2021 Feb; 218():107669. PubMed ID: 32835825
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lessons from the Cerebrospinal Fluid Analysis of HTLV-1-Infected Individuals: Biomarkers of Inflammation for HAM/TSP Development.
    Freitas NL; Gomes YCP; Souza FDS; Torres RC; Echevarria-Lima J; Leite ACCB; Lima MASD; Araújo AQC; Silva MTT; Espíndola OM
    Viruses; 2022 Sep; 14(10):. PubMed ID: 36298702
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical and laboratory features of HTLV-I asymptomatic carriers and patients with HTLV-I-associated myelopathy/tropical spastic paraparesis from the Brazilian Amazon.
    Takatani M; Crispim ME; Fraiji N; Stefani MM; Kiesslich D
    Rev Inst Med Trop Sao Paulo; 2017 Apr; 59():e5. PubMed ID: 28380116
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multicenter, randomized, double-blind, placebo-controlled phase 3 study of mogamulizumab with open-label extension study in a minimum number of patients with human T-cell leukemia virus type-1-associated myelopathy.
    Sato T; Nagai M; Watanabe O; Misu T; Takenouchi N; Ohkubo R; Ishihara S; Tsuboi Y; Katsuno M; Nakagawa M; Matsushita T; Aso Y; Matsuura E; Tokashiki T; Mukaino A; Adachi H; Nakanishi K; Yamaguchi Y; Yamaguchi S; Yamano Y
    J Neurol; 2024 Jun; 271(6):3471-3485. PubMed ID: 38430272
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Familial clusters of HTLV-1-associated myelopathy/tropical spastic paraparesis.
    Nozuma S; Matsuura E; Matsuzaki T; Watanabe O; Kubota R; Izumo S; Takashima H
    PLoS One; 2014; 9(5):e86144. PubMed ID: 24802839
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Levels of serum chemokines discriminate clinical myelopathy associated with human T lymphotropic virus type 1 (HTLV-1)/tropical spastic paraparesis (HAM/TSP) disease from HTLV-1 carrier state.
    Guerreiro JB; Santos SB; Morgan DJ; Porto AF; Muniz AL; Ho JL; Teixeira AL; Teixeira MM; Carvalho EM
    Clin Exp Immunol; 2006 Aug; 145(2):296-301. PubMed ID: 16879249
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HTLV-1 associated myelopathy/tropical spastic paraparesis (HAM/TSP): A comparative study to identify factors that influence disease progression.
    Matsuura E; Nozuma S; Tashiro Y; Kubota R; Izumo S; Takashima H
    J Neurol Sci; 2016 Dec; 371():112-116. PubMed ID: 27871430
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunovirological markers in HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP).
    Enose-Akahata Y; Jacobson S
    Retrovirology; 2019 Nov; 16(1):35. PubMed ID: 31783764
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term safety and efficacy of mogamulizumab (anti-CCR4) for treating virus-associated myelopathy.
    Sato T; Yamauchi J; Yagishita N; Araya N; Takao N; Ohta Y; Inoue E; Takahashi M; Yamagishi M; Suzuki Y; Uchimaru K; Matsumoto N; Hasegawa Y; Yamano Y
    Brain; 2023 Aug; 146(8):3181-3191. PubMed ID: 37093965
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-world clinical course of HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) in Japan.
    Tsutsumi S; Sato T; Yagishita N; Yamauchi J; Araya N; Hasegawa D; Nagasaka M; Coler-Reilly ALG; Inoue E; Takata A; Yamano Y
    Orphanet J Rare Dis; 2019 Oct; 14(1):227. PubMed ID: 31639014
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early Juvenile Human T-cell Lymphotropic Virus Type-1-Associated Myelopathy/Tropical Spastic Paraparesis: Study of 25 Patients.
    Varandas CMN; da Silva JLS; Primo JRL; de Oliveira MFSP; Moreno-Carvalho O; Farre L; Bittencourt AL
    Clin Infect Dis; 2018 Oct; 67(9):1427-1433. PubMed ID: 29912303
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential patterns of serum biomarkers of immune activation in human T-cell lymphotropic virus type I-associated myelopathy/tropical spastic paraparesis, and adult T-cell leukemia/lymphoma.
    Giusti RM; Maloney EM; Hanchard B; Morgan OS; Steinberg SM; Wachter H; Williams E; Cranston B; Fuchs D; Manns A
    Cancer Epidemiol Biomarkers Prev; 1996 Sep; 5(9):699-704. PubMed ID: 8877061
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HTLV-1 proviral load in peripheral blood mononuclear cells quantified in 100 HAM/TSP patients: a marker of disease progression.
    Olindo S; Lézin A; Cabre P; Merle H; Saint-Vil M; Edimonana Kaptue M; Signate A; Césaire R; Smadja D
    J Neurol Sci; 2005 Oct; 237(1-2):53-9. PubMed ID: 15972218
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of HTLV-1 virulence factors (HBZ, Tax, proviral load), HLA class I and plasma neopterin on manifestation of HTLV-1 associated myelopathy tropical spastic paraparesis.
    Tarokhian H; Taghadosi M; Rafatpanah H; Rajaei T; Azarpazhooh MR; Valizadeh N; Rezaee SAR
    Virus Res; 2017 Jan; 228():1-6. PubMed ID: 27845163
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incidence of human T cell lymphotropic virus type 1-associated myelopathy/tropical spastic paraparesis in a long-term prospective cohort study of initially asymptomatic individuals in Brazil.
    Romanelli LC; Caramelli P; Martins ML; Gonçalves DU; Proietti FA; Ribas JG; Araújo MG; Carneiro-Proietti AB
    AIDS Res Hum Retroviruses; 2013 Sep; 29(9):1199-202. PubMed ID: 23617363
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.